Document:

Exhibit
4.19

 

Shareholders
Agreement

 

This
Shareholders Agreement (the “Agreement”) is entered into effective as of February 9, 2017, by and between Kitov
Pharmaceuticals Holdings Ltd. an Israeli publicly traded corporation (“Parent”), on behalf of itself and, if
Parent is not the buyer of the shares previously held by GHP (as defined hereunder), also on behalf of an as yet undetermined
Affiliated party of Parent which shall, upon execution thereof by it, be deemed a Party to this Agreement Ab Initio (“Kitov”)
and Taoz – Company for Management of Companies Ltd. (“Taoz”); each of Kitov and Taoz a “Party”
and collectively the “Parties”.

 

WHEREAS,
in view of the recent developments, in connection with Kitov's acquisition of control in Tyrnovo Ltd. (hereinafter: the "Company"),
and the proceedings in the Tel Aviv District Court (Economics Division) commenced by Taoz in connection with that certain Term
Sheet executed by and among Taoz, the Company and the former controlling shareholder of the Company, Goldman Hirsh Partners Ltd.
(hereinafter: "GHP") on July 11, 2016 (hereinafter: "Investment Agreement"); and

 

WHEREAS,
Kitov and Taoz wish to mutually end the proceedings between Taoz on one hand and Kitov and the Company on the other in connection
with the Investment Agreement;

 

WHEREAS,
Kitov, Taoz and the Company have entered into that certain Binding Term Sheet dated February 1, 2017 (the “Binding Term
Sheet”) setting forth the arrangements for, among other matters, investments by Taoz into the Company, and that certain
Waiver and Release Agreement dated February 9, 2017 setting forth the arrangements for, among other matters, mutual waivers and
releases in connection with the Investment Agreement; and

 

WHEREAS,
the Parties have reached additional understandings relating to their relationship as shareholders of the Company;

 

NOW
THEREFORE, the Parties hereto agree as follows:

 

		1.	Both
                                         the Company and Kitov acknowledge the initial investment made by Taoz in the Company,
                                         prior to Kitov's acquisition of the Company's shares from GHP, in the amount of $250,000,
                                         in exchange for which 534 Ordinary Shares of the Company were issued to Taoz (hereinafter:
                                         the "First Investment").

 

		2.	Finance
                                         by Kitov. Kitov hereby undertakes to finance any future working capital requirement
                                         of the Company, up to an amount of $1,000,000, of which the amount of $750,000 shall
                                         be provided to the Company no later than 30 days from the execution of this Agreement
                                         and $250,000 pursuant with a business plan to be approved by the Board of Directors of
                                         the Company no later than three (3) months following the execution of this Agreement.
                                         Such financing by Kitov shall be provided by way of Convertible Loan (as defined in the
                                         Binding Term Sheet). Each Party undertakes to cause the Board to adopt an agreed business
                                         plan within the indicated period.

 

    	 	 	1 of 11

     

    

 

		3.	The
                                         transfer of shares of the Company from Kitov to an Affiliated party thereof, as set forth
                                         in the preamble to this Agreement shall be subject to the same preconditions applicable
                                         to a transfer to a Permitted Transferee, as set forth in the Binding Term Sheet.

 

		4.	In
                                         event that the Milestone (as defined in the Binding Term Sheet) was achieved, however
                                         Taoz did not invest the Deferred Investment (as defined in the Binding Term Sheet) then
                                         Kitov shall have the right, for a period of 60 days, to acquire all of the Taoz’s
                                         holdings in the Company at a price per share of US$ 476.48.

 

		5.	Participation
                                         in Increase of Shareholdings. In the event that Kitov increases its shareholdings
                                         in the Company, through the purchase of additional shares from the Company's current
                                         shareholders, by more than 1,500 shares of the Company (hereinafter: "Newly Acquired
                                         Shares") during a period of 12 months from the date hereof, then, Kitov shall
                                         notify Taoz once every calendar month of any purchases consummated by it during the previous
                                         calendar month (the “Kitov NAS Notice”) and Taoz shall notify Kitov,
                                         within 14 days of receipt of the Kitov NAS Notice (the “Taoz DNAS Notice”),
                                         if it wishes to purchase part of the Newly Acquired Shares, up to 30% of the Newly Acquired
                                         Shares, and the amount of Newly Acquired Shares, up to 30% of the Newly Acquired Shares,
                                         that it wishes to purchase (the “Designated Newly Acquired Shares”).

 

Taoz
shall be obligated to purchase, within a period of 12 months of delivery of the Taoz DNAS Notice as set forth above, (the “DNAS
Acquisition Deadline Date”), the Designated Newly Acquired Shares from Kitov at the New Shares PPS (defined below).

 

In
event that Taoz failed to purchase the Designated Newly Acquired Shares by the DNAS Acquisition Deadline Date (a “Taoz
DNAS Acquisition Failure”), Taoz shall immediately transfer to Kitov, as liquidated damages and not a penalty, and as
the sole remedy for such Taoz DNAS Acquisition Failure, for no consideration to be paid by Kitov, such number of securities equal
to 20% of the amount of shares included in the Designated Newly Acquired Shares which Taoz has failed to purchase, out of the
shares held by Taoz (the “Taoz Forfeited Securities”).

 

    	 	 	2 of 11

     

    

 

By
execution of this Agreement, Taoz does hereby appoint Kitov, or any duly authorized agent thereof, with full power of substitution
and resubstitution, in the event of a Taoz DNAS Acquisition Failure, as Taoz’s true and lawful attorney and irrevocable
proxy, to the fullest extent of the Taoz’s rights with respect to each Taoz Forfeited Security owned by it or over which
it has control, if Taoz is unable or unwilling to perform its obligations with respect to the transfer of the Taoz Forefeited
Securities (the “Proxy”). Taoz intends this Proxy to be irrevocable and coupled with an interest hereunder
and shall terminate at the earlier of: (i) the end of the term of this Agreement; or (ii) upon the consummation of the acquisition
of the Designated Newly Acquired Shares by Taoz as set forth above. Taoz hereby expressly and irrevocably revokes any, (i) proxies
previously granted with respect to each Taoz Forfeited Security owned by it or over which it has control and represents that none
of such previously-granted proxies are irrevocable, and/or, (ii) until the end of the term of this Agreement, any proxies it may
grant with respect to each Taoz Forfeited Security owned by it or over which it has control which are not in accordance with the
terms and conditions of this Agreement and any such proxies shall be deemed void ab initio, and to any such extent as such
may not be deemed void ab initio under any applicable legal doctrine, such shall nonetheless be deemed superseded and replaced
by the Proxy, which shall be deemed to have been issued later than any other such proxy.

 

The
“New Shares PPS” shall mean, (1) in the event that the Newly Acquired Shares are purchased by Kitov, in whole
or in part, in consideration for shares of Kitov, then during a period of six months from the Acquisition Date, an amount, in
cash equal to US$ 350 per share, and during a period commencing as of the lapse of six months and until the lapse of 12 months
from the Acquisition Date, an amount, in cash equal to US$ 403 per share. (2) in the event that all the Newly Acquired Shares
are purchased by Kitov for cash consideration only, then an amount, in cash, equal to 104% of the price per share actually paid
by Kitov as consideration for such Newly Acquired Shares. In such case Kitov shall furnish Taoz with the purchase agreements executed
with the former shareholders outlining the terms of purchase.

.

		6.	Right
                                         of First Refusal: Until an Exit Event, Taoz shall have a right of first refusal with
                                         respect to any transfer by Kitov (or a Permitted Transferee thereof) (the “Offeror”)
                                         of its shares in the Company, of any or all of its shares, in such quantities and under
                                         such terms and conditions as follows:

 

		6.1.	Kitov
                                         shall send to Taoz a written notice detailing the number of shares intended to be transferred
                                         or sold (the “Offered Shares”), the price and the other terms of the
                                         transfer or sale (the “Offer”). Taoz shall have a right to purchase
                                         only up to its Pro Rata Share (as defined in the Binding Term Sheet) of the Offered Shares
                                         by sending Kitov a written notice (the “Notice of Reply”) within a
                                         period of ten (10) business days after receipt of Offer, and under the terms of the Offer.
                                         If the Taoz does not accept in the abovementioned manner, then Taoz shall be regarded
                                         as having given a notice of refusal to purchase the Offered Shares or any part thereof.

 

    	 	 	3 of 11

     

    

 

		6.2.	The
                                         Notice of Reply shall constitute an agreement for the sale and purchase of the Pro Rata
                                         Share of the Offered Shares at the price and conditions, and by delivery of the same
                                         type consideration, as specified in the Offer.

 

		6.3.	Notwithstanding
                                         the foregoing, the right of first refusal as set forth above shall not apply with respect
                                         to a Transfer to a Permitted Transferee ("נעבר מותר")
                                         as defined in the Binding Term Sheet, so long as such Permitted Transferee shall execute
                                         in writing a joinder to this Agreement pursuant to which such transferee agrees to be
                                         bound by the terms of this Agreement as if an original party hereto.

 

		7.	Co-Sale:
                                         Until an Exit Event, in the event that Taoz did not purchase the Offered Shares under
                                         the Right of First Refusal as set forth above, Taoz shall have a right, exercisable upon
                                         written notice to Kitov within ten (10) business days after the receipt of the Offer,
                                         to participate in such transfer, by selling up to its Pro Rata Share out of the Offered
                                         Shares, on the same terms and conditions, for receipt of the same type of consideration,
                                         of the Offer (provided that such transfer is completed by Kitov). If Taoz does not accept
                                         in the abovementioned manner, then Taoz shall be regarded as having given a notice of
                                         refusal to participate in the sale of the Offered Shares or any part thereof. Notwithstanding
                                         the foregoing, the Co-Sale right as set forth above shall not apply with respect to a
                                         Transfer to a Permitted Transferee ("נעבר מותר")
                                         as defined above.

 

		8.	No-Sale:
                                         Until the earlier of (i) the lapse of 30 months from the date hereof; (ii) the execution
                                         of investment agreements by the Company with external non-affiliated investor (other
                                         than Kitov or a Company controlled by Kitov), according to which the Company shall issue
                                         10% or more of its issued share capital immediately prior to such issuance, , (iii) immediately
                                         prior to a Qualified Initial Public Offering ("IPO"), (iv) immediately prior
                                         to the consummation of a merger or sale of all or substantially all of the Company's
                                         assets or share capital (“M&A Transaction”, and together with an IPO,
                                         an “Exit Event”), or (v) the lapse of 60 days following the Company’s
                                         Milestone Notice, Kitov shall not make any transfer, except for: (i) up to 15% of the
                                         issued share capital of the Company or (ii) transfer to a Permitted Transferee.

 

		9.	Put
                                         Option. Kitov hereby provides to Taoz an option to sell to Kitov up to 50% of the
                                         shares issued to Taoz through the Initial Investment, Deferred Investment and the Option
                                         (as such terms are defined in the Binding Term Sheet) and any Designated Newly Acquired
                                         Shares actually acquired by Taoz, exercisable during a period of 90 days from the publication
                                         by the Company of the results of the Phase I clinical trials (the “Exercise
                                         Period”), for a price per share equal to US$1,600 (the “Exercise Price”).
                                         Subject to receipt by Kitov of an exercise notice from Taoz, the Exercise Price s hall
                                         be paid, 40 days after the delivery of the exercise notice, and subject to all required
                                         regulatory and corporate approvals including, without limitation the approval of the
                                         Tel Aviv Stock Exchange, in (1) ordinary shares of Kitov Pharmaceuticals Holdings Ltd.,
                                         at a price per share value (for each Kitov share) equal to the higher of (i) of NIS 1.824
                                         (subject to adjustments due to stock split and combination) and (ii) the average price
                                         of the shares of Kitov at the closing of trade on the Tel Aviv Stock Exchange during
                                         a period of 30 days following the lapse of the Exercise Period, or, according to Kitov’s
                                         sole discretion, (2) in cash. Upon the expiration of the Exercise Period, the Put Option,
                                         if not exercised by Taoz, shall expire and no longer be valid. The exercise of the Put
                                         Option shall be executed by providing Kitov with written notice of the Taoz's decision
                                         to sell all its shares under the Put Option.

 

    	 	 	4 of 11

     

    

 

		10.	Confidentiality

 

Each
party to this Agreement possesses Confidential Information (as defined below); and, each party in possession of Confidential Information
(the "Disclosing Party") may disclose some of its Confidential Information to the other party (the "Receiving
Party") during the term of this Agreement; and the Parties hereto agree as follows:

 

		10.1.	Notwithstanding
                                         any termination of this Agreement, the Receiving Party’s undertakings with respect
                                         to the Confidential Information (as defined below) shall remain valid and binding for
                                         a period of five (5) years after the termination of this Agreement.

 

		10.2.	For
                                         purposes of this Agreement: "Confidential Information" shall mean and
                                         include:

 

		10.2.1.	Trade
                                         Secrets and Technical Information (as hereinafter defined) and other information of the
                                         Disclosing Party of a confidential and/or proprietary nature or which could reasonably
                                         be expected to be confidential, whether written or oral, received by the Receiving Party
                                         from the Disclosing Party or to which the Receiving Party has access, and which relate
                                         to the business, technology, products, marketing and/or activities of the Disclosing
                                         Party, including but not limited to all copies, excerpts, modifications, translations,
                                         enhancements and adaptations of all the foregoing, whether made by the Receiving Party
                                         or otherwise,; "Trade Secrets" shall include, but not be limited to,
                                         technical and/or business information embodied in all drawings, designs, technical manuals,
                                         plans, proposals, marketing and sales plans, customer lists, financial information, costs,
                                         pricing information and product application data, owned or developed by the Disclosing
                                         Party; "Technical Information" shall mean all technical information,
                                         including but not limited to source code, object code, documentation, manuals, product
                                         plans, technical know-how, technical data, performance data, product specifications and
                                         other information of a technical nature whether or not contained or incorporated in drawings,
                                         photographs, memoranda, operational documents, models, prototypes, designs, quality control
                                         and test charts, manuals and methods; or

 

    	 	 	5 of 11

     

    

 

		10.2.2.	any
                                         information which is marked "confidential", or bears a marking of like import,
                                         or which the Disclosing Party states in writing at the time of transmittal to, or receipt
                                         by, the Receiving Party is to be considered confidential. Such writing shall be sufficiently
                                         specific to enable the Receiving Party to identify the information considered to be confidential
                                         by the Disclosing Party.

 

		10.3.	For
                                         avoidance of doubt it is clarified that this Agreement as well as any discussions held
                                         in connection with the Agreement, and any proposed terms and conditions with respect
                                         thereto, are deemed Confidential Information under this Agreement.

 

		10.4.	The
                                         Receiving Party shall (a) use the Confidential Information solely to the extent necessary
                                         for the purposes of this Agreement and shall not use the Confidential Information for
                                         any other purpose; (b) not disclose, communicate, divulge, disseminate or make available
                                         any Confidential Information to any entity or person other than as set forth herein this
                                         Agreement and shall restrict disclosure of the confidential Information to those of its
                                         officers, directors, employees, agents, accountants, attorneys, consultants or other
                                         professional advisors (collectively “Representatives”) who are bound
                                         by a written instrument to maintain the confidentiality and non-use of the Confidential
                                         Information in similar manner as provided by this Agreement; and (c) disclose the Confidential
                                         Information to its Representatives only to the extent it is strictly necessary for each
                                         such Representative to perform such duties for the Receiving Party. The Receiving Party
                                         shall take all reasonable steps, which may be necessary in order to enforce any undertaking
                                         by such Representatives with respect to the confidentiality, non-use or nondisclosure
                                         obligation by any such person in connection with the Confidential Information. Receiving
                                         Party is aware that Confidential Information not expressly approved for release hereunder
                                         may be deemed "Inside Information" under Israeli and/or US securities laws,
                                         and any use or disclosure thereof may be deemed a criminal offense in one or more jurisdictions.
                                         Receiving Party undertakes (i) not to make any unlawful use of Confidential Information,
                                         and, (ii) that while in possession of Confidential Information which is considered Inside
                                         Information, neither Receiving Party, nor any of its Representatives, while in possession
                                         of Confidential Information, shall directly or indirectly buy, sell, trade the securities
                                         of the Disclosing Party, and shall not advise any other entity with respect to the foregoing.
                                         Receiving Party is aware that any such activities may be deemed "Insider Trading"
                                         under Israeli and/or US securities laws, and any use or disclosure thereof may be deemed
                                         a criminal offense in one or more jurisdictions. Receiving Party represents that it is
                                         aware of, and will advise any of its Representatives, of the restrictions imposed by
                                         the applicable securities laws and regulations on the purchase or sale of securities
                                         by any person who has received non-public information regarding a company with publicly
                                         traded securities, as well as the restrictions making it unlawful to communicate such
                                         information to any other person when it is reasonably foreseeable that such other person
                                         is likely to purchase or sell securities in reliance upon such information.

 

    	 	 	6 of 11

     

    

 

		10.5.	Information
                                         shall not be deemed confidential, and the Receiving Party shall have no obligation with
                                         respect to any such information, which the Receiving Party can evidence, to the Disclosing
                                         Party by appropriate written and dated documentation:

 

		10.5.1.	is
                                         already known to the Receiving Party at or prior to the Effective Date; or

 

		10.5.2.	is
                                         or becomes publicly known through no wrongful act of the Receiving Party; or

 

		10.5.3.	is
                                         independently developed by the Receiving Party or is rightfully received by the Receiving
                                         Party from a third party without restriction and without breach of this Agreement; or

 

		10.5.4.	is
                                         approved for release by written authorization of the Disclosing Party.

 

		10.6.	Any
                                         Confidential Information is and shall always remain the exclusive property of the Disclosing
                                         Party, and the Receiving Party hereby acknowledges the right, title and interest of the
                                         Disclosing Party in and to the Confidential Information. The Receiving Party will not
                                         at any time infringe, contest, dispute or question such right, title or interest nor
                                         aid others in doing so directly or indirectly.

 

		10.7.	The
                                         Receiving Party shall use the same standard of care it uses to protect its own Confidential
                                         Information to avoid disclosure to, or misuse of by, any third party of any of the Disclosing
                                         Party’s Confidential Information for the duration of this Agreement and for a period
                                         of five (5) years from the date of the termination of this Agreement. In the event that
                                         the Receiving Party or any of its Representatives becomes legally compelled to disclose
                                         any of the Confidential Information, the Receiving Party shall provide the Disclosing
                                         Party with prompt written notice of such requirement, so that the Disclosing Party may
                                         seek a protective order or other appropriate remedy. In the event that such protective
                                         order or other remedy is not obtained, the Receiving Party will furnish only that minimum
                                         portion of the Confidential Information which the Receiving Party is advised by written
                                         opinion of its legal counsel is legally required, and shall exercise all commercially
                                         reasonable efforts to obtain assurances that confidential treatment will be accorded
                                         such disclosure. Neither party under this Agreement shall publicly announce or disclose
                                         the existence of this Agreement, or its contents, any discussions relating thereto, or
                                         the discussions of the purposes of this Agreement, without the prior written consent
                                         of the other party or except as may be required by law or by applicable rules of any
                                         stock exchange or quotation system on which such Party or its affiliates lists or trades
                                         securities.

 

    	 	 	7 of 11

     

    

 

		10.8.	All
                                         the Disclosing Party’s Confidential Information and all tangible forms of such
                                         information, including, but not limited to, business information, data, documents, drawings,
                                         specifications, prototypes, and software received hereunder by the Receiving Party from
                                         the Disclosing Party shall remain the property of the Disclosing Party. Upon written
                                         request by the Disclosing Party, the Receiving Party shall return to the Disclosing Party
                                         all tangible forms of the Disclosing Party Confidential Information, including any and
                                         all copies thereof, provided however, that the Receiving Party may keep one (1) copy
                                         of any Confidential Information for archival purposes only and such copy shall remain
                                         subject to the confidentiality obligations hereunder.

 

		10.9.	Neither
                                         this Agreement nor any disclosure of Confidential Information may be construed as: (i)
                                         granting any right, warranty, or license by implication or otherwise under any patent,
                                         copyright, know-how or design rights, or other form of protection of industrial or intellectual
                                         property; or (ii) obligating the Disclosing Party to furnish to the Receiving Party or
                                         any of its Representatives any Confidential Information.

 

		11.	Notices

 

All
notices and other communications made pursuant to or under this Agreement will be in writing and will be deemed to have been duly
given or made (a) when personally delivered, (b) when transmitted by facsimile or electronic mail if such transmission occurs
on a Business Day before 5:00 p.m. (recipient local time), or the next succeeding Business Day if such transmission occurs at
any other time, (c) three Business Days after deposit with a nationally recognized international overnight courier service, or
(d) ten Business Days after the mailing if sent or by registered or certified international mail, postage prepaid, return receipt
requested. All notices and other communications under this Agreement will be delivered to the addresses set forth below, or such
other address as such Party may have given to the other Parties by notice pursuant to this ‎Section 11:

 

If
to Taoz:

____________________________________________

_____________________________________________

 

If
to Kitov:

Kitov
Pharmaceuticals Holdings Ltd.

One
Azrieli Center, Round Tower, 23rd Floor

132
Menachem Begin Road

Email:
avraham@kitovpharma.com

Attention:
Avraham Ben-Tzvi, Adv.

 

    	 	 	8 of 11

     

    

 

		12.	Expenses.
                                         Except as otherwise provided herein, all fees and expenses incurred in connection
                                         with or related to the transactions contemplated hereby will be paid by the Party incurring
                                         such fees or expenses. In the event of termination of this Agreement, the obligation
                                         of each Party to pay its own expenses will be subject to any rights of such Party arising
                                         from a breach of this Agreement by the other.

 

		13.	Entire
                                         Agreement. This Agreement, and the Binding Term Sheet, constitute the entire agreement
                                         of the Parties relating to the subject matter hereof and thereof and supersedes all prior
                                         and contemporaneous agreements, negotiations, correspondence, Agreements and communications
                                         of the Parties, oral or written, with respect to the subject matter hereof.

 

		14.	Amendment;
                                         Waiver. This Agreement will not be amended, modified or waived in any manner without
                                         the consent in writing duly executed and delivered by each Party hereto. No failure or
                                         delay of any Party to exercise any right or remedy given to such Party under this Agreement
                                         and no custom or practice of the Parties in variance with the terms hereof, will constitute
                                         a waiver of any Party’s right to demand exact compliance with the terms hereof.
                                         Any written waiver will be limited to those items specifically waived therein and will
                                         not be deemed to waive any future breaches or violations or other non-specified breaches
                                         or violations unless, and to the extent, expressly set forth therein.

 

		15.	Severability.
                                         If any term or provision of this Agreement is held invalid, illegal or unenforceable
                                         in any respect under any applicable Law, the validity, legality and enforceability of
                                         all other terms and provisions of this Agreement will not in any way be affected or impaired.
                                         If the final judgment of a court of competent jurisdiction or other Governmental Authority
                                         declares that any term or provision hereof is invalid, illegal or unenforceable, the
                                         Parties agree that the court making such determination will have the power to reduce
                                         the scope, duration, area or applicability of the term or provision, to delete specific
                                         words or phrases, or to replace any invalid, illegal or unenforceable term or provision
                                         with a term or provision that is valid, legal and enforceable and that comes closest
                                         to expressing the intention of the invalid, illegal or unenforceable term or provision.

 

		16.	Governing
                                         Law. This Agreement will be construed and enforced in accordance with, and will be
                                         governed exclusively by, the internal Laws of the State of Israel, without giving effect
                                         to any Law or rule that would cause the Laws of any jurisdiction other than the State
                                         of Israel to be applied.

 

		17.	Exclusive
                                         Jurisdiction. The competent courts of Tel-Aviv, Israel shall have exclusive jurisdiction
                                         in all matters relating to any dispute arising out of or relating to this Agreement,
                                         or the breach thereof, to the exclusion of any other jurisdiction. Each of the Parties
                                         (a) irrevocably consents to the exclusive jurisdiction and venue of the court as set
                                         forth above, (b) agrees that process may be served upon them in any manner authorized
                                         by the court for such persons, (c) waives the defense of an inconvenient forum and covenants
                                         not to assert or plead any objection which they might otherwise have to such jurisdiction,
                                         venue and such process, and (d) agrees that a final judgment in such proceeding shall
                                         be final, binding and enforceable in any court of competent jurisdiction.

 

    	 	 	9 of 11

     

    

 

		18.	Rules
                                         of Construction

 

The
following rules of construction will govern the interpretation of this Agreement:

 

		18.1.	all
                                         references to Articles, Sections or Schedules are to Articles, Sections or Schedules
                                         in this Agreement, unless otherwise stated explicitly;

 

		18.2.	each
                                         accounting term not otherwise defined in this Agreement has the meaning assigned to it
                                         in accordance with generally accepted accounting principles in the State of Israel;

 

		18.3.	unless
                                         the context otherwise requires, words in the singular or plural include the singular
                                         and plural, and pronouns stated in either the masculine, the feminine or neuter gender
                                         will include the masculine, feminine and neuter;

 

		18.4.	whenever
                                         the words “include,” “includes” or “including” are
                                         used in this Agreement they will be deemed to be followed by the words “but not
                                         limited to”;

 

		18.5.	the
                                         word “extent” in the phrase “to the extent” will mean the degree
                                         to which a subject or other thing extends, and such phrase will not simply mean “if”;

 

		18.6.	references
                                         to any statute, rule, regulation or form (including in the definition thereof) will be
                                         deemed to include references to such statute, rule, regulation or form as amended, modified,
                                         supplemented or replaced from time to time (and, in the case of any statute, include
                                         any rules and regulations promulgated under such statute), and all references to any
                                         section of any statute, rule, regulation or form include any successor to such section;

 

		18.7.	time
                                         is of the essence with regard to all dates and time periods set forth or referred to
                                         in this Agreement;

 

		18.8.	the
                                         subject headings of Articles and Sections of this Agreement are included for purposes
                                         of convenience of reference only and will not affect the construction or interpretation
                                         of any of its provisions;

 

		18.9.	(i)
                                         the terms “hereof”, “herein”, “hereby”, “hereto”,
                                         and derivative or similar words refer to this entire Agreement, including the Schedules
                                         and Exhibits hereto, (ii) the term “any” means “any and all”
                                         and (iii) the term “or” will not be exclusive and will mean “and/or”;

 

		18.10.	(i)
                                         references to “days” means calendar days unless Business Days are expressly
                                         specified, (ii) references to “NIS” mean New Israeli Shekels and (iii) references
                                         to “$” mean U.S. dollars;

 

		18.11.	the
                                         Parties have participated jointly in the negotiation and drafting of this Agreement;
                                         in the event an ambiguity or question of intent or interpretation arises, this Agreement
                                         will be construed as if drafted jointly by the Parties, and no presumption or burden
                                         of proof will arise favoring or disfavoring any Party by virtue of the authorship of
                                         any of the provisions hereof and the language used will be deemed to be the language
                                         chosen by the Parties to express their mutual intent.

 

		19.	Counterparts;
                                         Deliveries. This Agreement may be executed simultaneously in counterparts, each of
                                         which will be deemed an original but all of which together will constitute one and the
                                         same instrument. This Agreement and any amendments hereto or thereto, to the extent signed
                                         and delivered by means of electronic transmission of .pdf files or other image files
                                         via e-mail, cloud-based transfer or file transfer protocol, or use of a facsimile machine,
                                         will be treated in all manners and respects and for all purposes as an original agreement
                                         or instrument and will be considered to have the same binding legal effect as if it were
                                         the original signed version thereof delivered in person. No party to any such agreement
                                         or instrument will raise the use of electronic transmission or a facsimile machine to
                                         deliver a signature or the fact that any signature or agreement or instrument was transmitted
                                         or communicated through the use of electronic transmission or a facsimile machine as
                                         a defense to the formation or enforceability of a contract, and each such party forever
                                         waives any such defense.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	 	 	10 of 11

     

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement on the date first above written.

 

 

__________________________________________

 

TAOZ
– COMPANY FOR MANAGEMENT AND HOLDINGS OF COMPANIES LTD.

 

	By:		 
	Title:		 

 

__________________________________________

 

Kitov
Pharmaceuticals Holdings Ltd. an Israeli publicly
traded corporation (“Parent”), on behalf of itself and, if Parent is not the buyer of the shares previously
held by Goldman Hirsh Partners Ltd., also on behalf of an as yet undetermined Affiliated party of Parent (“Kitov”)
which shall, upon execution hereof by it, be deemed a Party to this Agreement Ab Initio.

 

	By:		 
	Title:		 

 

 

11
of 11Exhibit

Exhibit 10.1
HARSCO CORPORATION
2013 Equity and incentive Compensation Plan
Amendment No. 1

WHEREAS, the Board of Directors and stockholders of Harsco Corporation (the “Company”) have adopted the 2013 Equity and Incentive Compensation Plan (the “Plan”); 
WHEREAS, pursuant to Section 3(a) of the Plan, a total of 6,800,000 shares of the common stock, par value $1.25 per share, of the Company (the “Common Stock”) have been reserved for issuance under the Plan; 
WHEREAS, the Company desires to increase the number of shares issuable under the Plan to 7,800,000 shares, including shares previously issued thereunder, and to increase the aggregate limit on the number of shares that may be issued or transferred in connection with awards other than stock options or appreciation rights to 4,621,000 shares; and 
WHEREAS, Section 18 of the Plan permits the Company to amend the Plan from time to time, subject only to certain limitations specified therein; 
NOW, THEREFORE, the following amendments and modifications are hereby made a part of the Plan subject to, and effective as of the date of, the approval of stockholders of the Plan as amended at the Company’s Annual Meeting of Stockholders on April 25, 2017:
1.Section 3(a) of the Plan shall be, and hereby is, amended such that the first sentence of such section shall hereby read as follows::
“Subject to adjustment as provided in Section 11 of this Plan, the number of shares of Common Stock that may be issued or transferred (A) upon the exercise of Option Rights or Appreciation Rights, (B) as Restricted Stock and released from substantial risks of forfeiture thereof, (C) in payment of Restricted Stock Units, (D) in payment of Performance Shares or Performance Units that have been earned, (E) as awards contemplated by Section 9 of this Plan, or (F) in payment of dividend equivalents paid with respect to awards made under the Plan will not exceed in the aggregate 7,800,000  shares; provided, that notwithstanding anything in this Section 3, or elsewhere in this Plan, to the contrary and subject to adjustment as provided in Section 11 of this Plan, the aggregate number of shares of Common Stock actually issued or transferred by the 

Company in connection with awards other than Option Rights or Appreciation Rights granted under this Plan will not exceed 4,621,000 shares.”

2.Section 3(b) of the Plan shall be, and hereby is, amended to increase the limit on the aggregate number of shares that may be issued or transferred upon the exercise of Incentive Stock Options to 7,800,000, and the first sentence of such section is thereby to read as follows::
“Notwithstanding anything in this Section 3, or elsewhere in this Plan, to the contrary and subject to adjustment as provided in Section 11 of this Plan, the aggregate number of shares of Common Stock actually issued or transferred by the Company upon the exercise of Incentive Stock Options will not exceed 7,800,000 shares.”
3.In all other respects, the Plan, as amended, is hereby ratified and confirmed and shall remain in full force and effect.

IN WITNESS WHEREOF, the Company has executed this Amendment No. 1 to the 2013 Equity and Incentive Compensation Plan.
                
HARSCO CORPORATION

By: /s/ Russell C. Hochman 
            
Name: Russell C. Hochman 
Title: Corporate Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}]]